Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.34
NAS:ACRX's Cash to Debt is ranked higher than
58% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. NAS:ACRX: 4.34 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ACRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.31  Med: 3.74 Max: N/A
Current: 4.34
Equity to Asset 0.03
NAS:ACRX's Equity to Asset is ranked lower than
92% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NAS:ACRX: 0.03 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ACRX' s Equity to Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.48 Max: 0.69
Current: 0.03
-0.01
0.69
F-Score: 2
Z-Score: -2.36
M-Score: -1.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -255.73
NAS:ACRX's Operating margin (%) is ranked lower than
83% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. NAS:ACRX: -255.73 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ACRX' s Operating margin (%) Range Over the Past 10 Years
Min: -1805.22  Med: -721.66 Max: -22.6
Current: -255.73
-1805.22
-22.6
Net-margin (%) -347.94
NAS:ACRX's Net-margin (%) is ranked lower than
86% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. NAS:ACRX: -347.94 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ACRX' s Net-margin (%) Range Over the Past 10 Years
Min: -1875.09  Med: -639.31 Max: -79.4
Current: -347.94
-1875.09
-79.4
ROE (%) -194.28
NAS:ACRX's ROE (%) is ranked lower than
94% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. NAS:ACRX: -194.28 )
Ranked among companies with meaningful ROE (%) only.
NAS:ACRX' s ROE (%) Range Over the Past 10 Years
Min: -194.28  Med: -58.42 Max: -43.78
Current: -194.28
-194.28
-43.78
ROA (%) -36.68
NAS:ACRX's ROA (%) is ranked lower than
75% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. NAS:ACRX: -36.68 )
Ranked among companies with meaningful ROA (%) only.
NAS:ACRX' s ROA (%) Range Over the Past 10 Years
Min: -134.55  Med: -73.84 Max: -22.78
Current: -36.68
-134.55
-22.78
ROC (Joel Greenblatt) (%) -306.74
NAS:ACRX's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. NAS:ACRX: -306.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ACRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1434.7  Med: -907.22 Max: -173.98
Current: -306.74
-1434.7
-173.98
Revenue Growth (3Y)(%) 58.90
NAS:ACRX's Revenue Growth (3Y)(%) is ranked higher than
97% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NAS:ACRX: 58.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ACRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 58.9
Current: 58.9
0
58.9
EBITDA Growth (3Y)(%) -34.80
NAS:ACRX's EBITDA Growth (3Y)(%) is ranked lower than
91% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. NAS:ACRX: -34.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ACRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -65.6 Max: -12.2
Current: -34.8
EPS Growth (3Y)(%) -26.50
NAS:ACRX's EPS Growth (3Y)(%) is ranked lower than
83% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NAS:ACRX: -26.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ACRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -64.9 Max: -7.8
Current: -26.5
» NAS:ACRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ACRX Guru Trades in Q2 2015

Paul Tudor Jones 24,100 sh (-54.18%)
» More
Q3 2015

ACRX Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
Q2 2016

ACRX Guru Trades in Q2 2016

Jim Simons 21,100 sh (New)
» More
Q3 2016

ACRX Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:CGNT, NAS:FONR, NAS:PAVM, NAS:VRAY, NAS:IRMD, NAS:IRIX, NAS:RTIX, NAS:AVGR, NAS:DRAD, AMEX:CVRS, NAS:EDAP, NAS:EYES, OTCPK:QTVLF, NAS:TNDM, OTCPK:ARTH, NAS:SPNE, NAS:VIVE, NAS:SRTS, NAS:MSON, OTCPK:AVMXF » details
Traded in other countries:R5X.Germany,
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of therapies for the treatment of acute pain.

AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialty pharmaceutical company engaged in the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company's main product candidate, Zalviso, formerly known as the Sufentanil NanoTab PCA System, or ARX-01, is currently under review by the FDA for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal for the commercialization of Zalviso in Europe and Australia. Its sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Its registered trademarks include ACELRX and NANOTAB.

Ratios

vs
industry
vs
history
P/B 38.86
ACRX's P/B is ranked lower than
98% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. ACRX: 38.86 )
Ranked among companies with meaningful P/B only.
ACRX' s P/B Range Over the Past 10 Years
Min: 2.13  Med: 6.2 Max: 77.52
Current: 38.86
2.13
77.52
P/S 10.00
ACRX's P/S is ranked lower than
85% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. ACRX: 10.00 )
Ranked among companies with meaningful P/S only.
ACRX' s P/S Range Over the Past 10 Years
Min: 4.69  Med: 34.5 Max: 2370
Current: 10
4.69
2370
Current Ratio 6.24
ACRX's Current Ratio is ranked higher than
85% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. ACRX: 6.24 )
Ranked among companies with meaningful Current Ratio only.
ACRX' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 5.29 Max: 20.39
Current: 6.24
0.43
20.39
Quick Ratio 6.15
ACRX's Quick Ratio is ranked higher than
87% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. ACRX: 6.15 )
Ranked among companies with meaningful Quick Ratio only.
ACRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 5.26 Max: 20.39
Current: 6.15
0.43
20.39
Days Inventory 27.32
ACRX's Days Inventory is ranked higher than
93% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. ACRX: 27.32 )
Ranked among companies with meaningful Days Inventory only.
ACRX' s Days Inventory Range Over the Past 10 Years
Min: 27.32  Med: 48.05 Max: 48.05
Current: 27.32
27.32
48.05
Days Sales Outstanding 57.96
ACRX's Days Sales Outstanding is ranked higher than
64% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. ACRX: 57.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.96  Med: 62.26 Max: 62.26
Current: 57.96
57.96
62.26
Days Payable 45.14
ACRX's Days Payable is ranked lower than
61% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. ACRX: 45.14 )
Ranked among companies with meaningful Days Payable only.
ACRX' s Days Payable Range Over the Past 10 Years
Min: 45.14  Med: 321.9 Max: 321.9
Current: 45.14
45.14
321.9

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.90
ACRX's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ACRX: -6.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -303.2  Med: -30.7 Max: 0
Current: -6.9
-303.2
0

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 41.43
ACRX's Price/Tangible Book is ranked lower than
94% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 4.06 vs. ACRX: 41.43 )
Ranked among companies with meaningful Price/Tangible Book only.
ACRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.08  Med: 6.1 Max: 57.58
Current: 41.43
2.08
57.58
Price/Median PS Value 0.30
ACRX's Price/Median PS Value is ranked higher than
93% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. ACRX: 0.30 )
Ranked among companies with meaningful Price/Median PS Value only.
ACRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 0.94 Max: 65.57
Current: 0.3
0.14
65.57
Earnings Yield (Greenblatt) (%) -57.83
ACRX's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ACRX: -57.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -65.57  Med: 3.75 Max: 9.1
Current: -57.83
-65.57
9.1

More Statistics

Revenue (TTM) (Mil) $12.65
EPS (TTM) $ -0.98
Beta2.88
Short Percentage of Float12.92%
52-Week Range $2.40 - 5.01
Shares Outstanding (Mil)45.33

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 15 10 40 83
EPS ($) -0.98 -1.03 -0.55 0.25
EPS w/o NRI ($) -0.98 -1.03 -0.55 0.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:ACRX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Dec 01 2016
AcelRx Pharmaceuticals Updates Agenda for Analyst & Investor Event Focusing on Innovative Therapies... Nov 28 2016
Edited Transcript of ACRX earnings conference call or presentation 1-Nov-16 8:30pm GMT Nov 21 2016
AcelRx Pharmaceuticals Unveiling Results of ARX-04 SAP303 Study in Post-Operative Setting at the... Nov 17 2016
AcelRx Pharmaceuticals to Host Analyst & Investor Event on December 1, 2016 Nov 09 2016
ACELRX PHARMACEUTICALS INC Financials Nov 08 2016
AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in November Nov 08 2016
ETF’s with exposure to AcelRx Pharmaceuticals, Inc. : November 4, 2016 Nov 04 2016
AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016 Nov 03 2016
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 03 2016
ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 02 2016
AcelRx Pharmaceuticals reports 3Q loss Nov 01 2016
AcelRx Pharmaceuticals reports 3Q loss Nov 01 2016
AcelRx Pharmaceuticals Provides Corporate Update and Reports Third Quarter and Nine Months 2016... Nov 01 2016
Q3 2016 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close Nov 01 2016
AcelRx Pharmaceuticals to Present ARX-04 Analysis for Treatment of Moderate-to-Severe Acute Pain in... Oct 31 2016
AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on... Oct 25 2016
AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings at National Conference on... Oct 24 2016
ETF’s with exposure to AcelRx Pharmaceuticals, Inc. : October 20, 2016 Oct 20 2016
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Oct 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)